Zillow slams popular architecture blog for using its photos of bad houses
Thiem exits early in Antalya tennis
Home Credit's Russian bank suspends IT systems after cyber attack
Synergy Pharmaceuticals Inc (NASDAQ:SGYP) & Synchrony Financial (NYSE:SYF) Watch List
20 April 2017, 05:40 | Kelvin Horton
The share price is now down -34.32% for the past three months. Finally, Guggenheim reaffirmed an "outperform" rating and issued a $10.00 price objective on shares of Synergy Pharmaceuticals in a research note on Thursday, March 2nd. Shares are trading 1.35% above their 50-day moving average, and 15.29% below their 200-day moving average.
Price Target is basically a projection of future price of a company's stock by the expert analysis of investment analysts or investment firms. Analyst's mean target price for PM is $114.14 while analysts mean recommendation is 2.50. These analysts and investment firms use various valuation methods to decide a price target for a stock.
Synergy Pharmaceuticals, Inc. (SGYP) has a market capitalization of 930.39 Million which suggests the company is a huge company further suggesting that the shares of Synergy Pharmaceuticals, Inc. The company has a consensus rating of Buy and an average price target of $11.63.
WARNING: "Synergy Pharmaceuticals Inc (SGYP) Shares Bought by Tudor Investment Corp Et Al" was first posted by BBNS and is the sole property of of BBNS.
Shares outstanding are recorded as 223.12 M and total shares floated are 215.24 M. Current ratio which is the relationship between current assets and current liabilities, indicating the liquidity of a business is calculated as 1.20. Analysts have a mean recommendation of 2.50 on this stock (A rating of less than 2 means buy, "hold" within the 3 range, "sell" within the 4 range, and "strong sell" within the 5 range).
Synergy Pharmaceuticals (NASDAQ:SGYP) opened at 4.55 on Tuesday. This is built on a simplified 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell.
Tudor Investment Corp Et Al increased its position in Synergy Pharmaceuticals Inc (NASDAQ:SGYP) by 1.3% during the fourth quarter, according to its most recent disclosure with the SEC. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.20) by $0.11. The analysts offering Earnings Estimates for the company were believing that Synergy Pharmaceuticals, Inc. The difference between Actual EPS and Estimated EPS was -0.11 Percent. Institutional investors and hedge funds own 55.36% of the company's stock. (SGYP) now has a value of $4.17 while the company's 52 week low is at $2.62, the shares dropped to the 52 week low on 05/12/16. The stock appeared -38.18% below its 52-week highs and is up 3.76% for the last five trades. The stock traded at a volume of 5.19 million shares. The Moving Average SMA50 is -21.5% while SMA200 is -20.89%. Equities research analysts predict that Synergy Pharmaceuticals Inc will post ($0.72) EPS for the current fiscal year. The Return on Investment (ROI) is at 0% while it's Return on Equity (ROE) value stands at -876.7%.
Johnson & Johnson (NYSE:JNJ) have shown a high EPS growth of 11.20% in the last 5 years and has earnings growth of 20.10% yoy. This is a near-term estimation for the next 12-18 months. The last session's volume of 5.20 million shares was lower than its average volume of 6.70 million shares. Aperio Group LLC now owns 22,346 shares of the biopharmaceutical company's stock valued at $123,000 after buying an additional 7,249 shares in the last quarter. The stock now has Weekly Volatility of 4.47% and Monthly Volatility of 5.24%. SGYP has P/E (Price to Earnings ttm) value of 0, Forward P/E of 0, P/C (Price to cash per share) of 11.1 and Price to Free Cash Flow (P/FCF) value of 0.
Samsung Galaxy S8, Galaxy S8+ India Launch Announced
In addition the phones in India will come with Exynos processor, so we can add another Rs 5000 to the price of both the phones. Bixby is also expected to arrive for other Galaxy devices like Galaxy S7 and S7 Edge and Galaxy S6 and S6 Edge.
Atlanta Hawks vs Washington Wizards NBA Playoffs 2017 schedule
Not coincidentally, Millsap dominated the third quarter with 14 points, including six during a 13-0 that put Atlanta up 74-67. Neither team had more than a two-possession lead until Butler made three free throws with 4 minutes to play to make it 95-88.
CJ McCollum erupts in Trail Blazers' Game 1 loss
Warriors: Thompson matched Hall of Famer Rick Barry for second place on the franchise list for postseason games played with 66. Behind a 28-12 3rd quarter advantage, the Warriors rolled to a 110-81 win over the Portland Trail Blazers Wednesday night.